Gyroscope Therapeutics
Latest round
- Series C
Last raised
- Mar 2021
Total raised
- $258M
Investors
- 6
About Gyroscope Therapeutics
Based in London, UK, and founded in 2016, Gyroscope Therapeutics Limited operates as a clinical-stage gene therapy company that develops gene therapies for ocular diseases. The company was founded by Khurem Farooq. Gyroscope Therapeutics Limited is a developer of a gene therapy GT005 a treatment for eye diseases. The company also plans to list on the Nasdaq under the symbol VISN.
Who invested in Gyroscope Therapeutics
6 investors across 4 rounds
See all investors in Gyroscope Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Gyroscope Therapeutics
Who invested in Gyroscope Therapeutics?
Gyroscope Therapeutics has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gyroscope Therapeutics raised?
Gyroscope Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Gyroscope Therapeutics last raise money?
Gyroscope Therapeutics's most recent round on record is a Series C, in Mar 2021.
What does Gyroscope Therapeutics do?
Based in London, UK, and founded in 2016, Gyroscope Therapeutics Limited operates as a clinical-stage gene therapy company that develops gene therapies for ocular diseases.
Where is Gyroscope Therapeutics headquartered?
Gyroscope Therapeutics is headquartered in London, UK.
Which VCs invest in companies like Gyroscope Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Gyroscope Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Gyroscope Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.